Physician profile
Cheryl D Wright
NPI 1790896140
$4,296.16
in general payments reported to CMS, 2019-2025
13 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $61.68 · 2021: $470 · 2022: $418 · 2023: $380 · 2024: $830 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097 · Consulting Fee: $425 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,097.46 |
| Consulting Fee | $425.00 |
| Education | $136.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,514.21 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $683.86 | 2019-2025 | Evenity, Otezla, Enbrel |
| Janssen Biotech, INC. | $587.77 | 2022-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $447.98 | 2019-2025 | |
| Ucb, INC. | $322.89 | 2023-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $282.51 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $145.51 | 2022 | |
| Novo Nordisk INC | $107.59 | 2021 | |
| Pfizer INC. | $79.74 | 2022-2025 | |
| Genzyme Corporation | $44.71 | 2020 | |
| Sandoz INC. | $42.04 | 2025 | Hyrimoz |
| Galderma Laboratories, L.P. | $20.27 | 2025 | Nemluvio |
| Radius Health, INC. | $17.08 | 2024 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.